News

Drug Patent & Exclusivity Expiration Report - Week of Feb 03 2025

Views: 44     Author: Unibest Industrial     Publish Time: 2025-02-03      Origin: Site

facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
sharethis sharing button

Patent and Exclusivity Expirations Report

Report generated for the week of 2025-02-03 by Unibest Digital Center. Current analysis scope only include the US FDA.



Summary of Expirations

This week, there are 4 drugs in the patent and exclusivity list. They are:
- BRISTOL MYERS SQUIBB CO's SPRYCEL, containing active ingredient DASATINIB
- AMERICAN REGENT INC's INJECTAFER, containing active ingredient FERRIC CARBOXYMALTOSE
- ABBVIE INC's KYBELLA, containing active ingredient DEOXYCHOLIC ACID
- MERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC's ZOLINZA, containing active ingredient VORINOSTAT

Patents Expiring This Week

DASATINIB - TABLET;ORAL - SPRYCEL

From BRISTOL MYERS SQUIBB CO; for treating Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia.


Dasatinib


20MG; 50MG; 70MG

Approved in Jun 28, 2006, used as Reference Listed Drug

100MG

Approved in May 30, 2008, used as Reference Listed Drug and Reference Standard


140MG; 80MG

Approved in Oct 28, 2010, used as Reference Listed Drug


There are 3 future patent(s) for this application. The earliest expires on 2025-08-04, and the latest expires on 2026-09-28.

Patent No Patent Expiration Date Patent Title
8680103 2025-02-04 Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors


DEOXYCHOLIC ACID - SOLUTION;SUBCUTANEOUS - KYBELLA

From ABBVIE INC; a cytolytic agent injected subcutaneously to improve the appearance submental fat.


Deoxycholic Acid


20MG/2ML (10MG/ML)

Approved in Apr 29, 2015, used as Reference Listed Drug and Reference Standard

There are 14 future patent(s) for this application. The earliest expires on 2025-08-03, and the latest expires on 2030-03-02.

Patent No Patent Use Code Patent Use Definition Patent Expiration Date Patent Title
8846066 U-1690 METHOD FOR REDUCTION OF SUBMENTAL FAT 2025-02-08 Methods and related compositions for reduction of fat and skin tightening



FERRIC CARBOXYMALTOSE - SOLUTION;INTRAVENOUS - INJECTAFER

From AMERICAN REGENT INC; an iron replacement therapy used to treat iron deficiency anemia in children and adults with intolerance or inadequate clinical response to oral iron, and in adult patients who have non-dialysis dependent chronic kidney disease.


Ferric carboxymaltose


750MG IRON/15ML (50MG IRON/ML)

Approved in Jul 25, 2013, used as Reference Listed Drug and Reference Standard

500MG IRON/10ML (50MG IRON/ML)

Approved in Oct 8, 2020, used as Reference Listed Drug and Reference Standard

1GM IRON/20ML (50MG IRON/ML)

Approved in Apr 28, 2021, used as Reference Listed Drug and Reference Standard

100MG IRON/2ML (50MG IRON/ML)

Approved in Feb 4, 2022, used as Reference Listed Drug and Reference Standard


In the issue of 2024-11-18, the exclusivity of NEW PATIENT POPULATION for Injectafer has expired. 


There are 5 future patent(s) for this application. The earliest expires on 2027-01-08, and the latest expires on 2028-02-15.

Patent No Patent Expiration Date Patent Title
7612109 2025-02-05 Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes


VORINOSTAT - CAPSULE;ORAL - ZOLINZA

From MERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC; for the treatment of cutaneous manifestations in patients with progressive, persistent, or recurrent cutaneous T- cell lymphoma (CTCL) following prior systemic therapies.


Vorinostat


100MG

Approved in Oct 6, 2006, used as Reference Listed Drug and Reference Standard

There are 3 future patent(s) for this application. The earliest expires on 2026-05-16, and the latest expires on 2028-03-18.

Patent No Patent Use Code Patent Use Definition Patent Expiration Date Patent Title
7399787 U-892 TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) 2025-02-09 Methods of treating cancer with HDAC inhibitors


Exclusivities Expiring This Week

No expirations this week.